LB-100 is a potent and selective inhibitor of protein phosphatase 2A (PP2A), an enzyme involved in the regulation of multiple cellular processes including cell cycle progression, DNA damage response, and apoptosis. Its primary application lies in cancer research and potential therapeutic development. By inhibiting PP2A, LB-100 enhances signaling pathways that promote cancer cell death and increases the sensitivity of tumor cells to chemotherapy and radiation. It has shown promising results in preclinical studies across various cancer types, including glioblastoma, pancreatic cancer, and sarcomas, where it improves the efficacy of conventional treatments. LB-100 can disrupt DNA repair mechanisms in cancer cells, making them more vulnerable to DNA-damaging agents. This property is being explored in combination therapies to overcome treatment resistance. Additionally, LB-100 has demonstrated the ability to cross the blood-brain barrier, making it particularly valuable in treating central nervous system tumors. Due to its broad-spectrum activity and synergy with existing anticancer agents, LB-100 is under investigation as an adjuvant in oncology regimens, with ongoing research focused on optimizing dosing and minimizing toxicity in clinical settings.